Researchers at the University of Tsukuba conducted a three-year observational study (January 2019–December 2021) using a ...
A new study published in Therapeutic Innovation & Regulatory Science provides crucial insights into the design and ...
The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...